Fetcroja | European Medicines Agency (EMA)

[ad_1]

Overview

Fetcroja is an antibiotic used in adults to treat infections caused by bacteria classed as aerobic Gram-negative bacteria. It is for use when other treatments might not work.

Fetcroja contains the active substance cefiderocol.

Fetcroja can only be obtained with a prescription. It should only be used after taking advice from a doctor with appropriate experience of managing patients with infectious diseases.

Fetcroja is given by infusion (drip) into a vein over 3 hours. The usual dose is 2 g given every 8 hours and the duration of treatment depends on the nature of the infection.

For more information about using Fetcroja, see the package leaflet or contact your doctor or pharmacist.

The active substance in Fetcroja, cefiderocol, belongs to the cephalosporin class of antibiotics. It uses the bacteria’s own system for importing iron to enter the bacterial cell, where it blocks the formation of the bacterial cell wall, killing the bacteria.

Fetcroja was tested in 2 main studies involving patients with various infections caused by Gram-negative bacteria.

In the first study, involving 452 adults with complicated urinary tract infection, 73% of patients treated with Fetcroja were cured (based on lack of symptoms and tests for bacteria in the urine) compared with 55% of patients treated with imipenem and cilastatin given together.

The second study involved 152 adults with various serious infections caused by bacteria that were resistant to carbapenems (could not be killed by antibiotics called carbapenems). For lung infections, 50% of patients treated with Fetcroja were cured based on a lack of symptoms, compared with 53% of those treated with the best alternative treatment. For bloodstream infections, these figures were 44% and 43%, respectively. For complicated urinary tract infections, 53% of patients treated with Fetcroja were cleared of disease-causing bacteria in the urine compared with 20% of patients receiving the best alternative treatment.

The most common side effects (which may affect up to 1 in 10 people) were diarrhoea, vomiting, nausea (feeling sick) and cough. For the full list of side effects with Fetcroja, see the package leaflet.

Fetcroja must not be used in patients who are hypersensitive (allergic) to any cephalosporin antibiotic or who have had a severe reaction to the broader class of beta-lactam antibiotics (such as penicillins or carbapenems). For the full list of restrictions, see the package leaflet.

The European Medicines Agency noted that the number of patients in the main studies was small. However, taken together with laboratory studies and studies on how the medicine works in the body, there was sufficient evidence that Fetcroja is effective against infections caused by aerobic Gram- negative bacteria. The Agency therefore decided that Fetcroja’s benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fetcroja have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Fetcroja are continuously monitored. Side effects reported with Fetcroja are carefully evaluated and any necessary action taken to protect patients.

Fetcroja received a marketing authorisation valid throughout the EU on 23 April 2020.

English (EN)
(106.82 KB – PDF)

First published: 29/04/2020Last updated: 04/05/2020

View

English (EN)
(336.06 KB – PDF)

First published: 29/04/2020

View

Product information

English (EN)
(591.05 KB – PDF)

First published: 29/04/2020Last updated: 22/01/2025

View

Latest procedure affecting product information:
R/0022

13/01/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(39.88 KB – PDF)

First published: 29/04/2020

View

Product details

Name of medicine: Fetcroja
Active substance: cefiderocol sulfate tosilate
International non-proprietary name (INN) or common name: cefiderocol
Therapeutic area (MeSH): Gram-Negative Bacterial Infections
Anatomical therapeutic chemical (ATC) code: J01D

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Fetcroja is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4 and 5.1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

[ad_2]

Source link

Fetcroja | European Medicines Agency (EMA)

Overview

How is Fetcroja used?

How does Fetcroja work?

What benefits of Fetcroja have been shown in studies?

What are the risks associated with Fetcroja?

Why is Fetcroja authorised in the EU?

What measures are being taken to ensure the safe and effective use of Fetcroja?

Other information about Fetcroja

Product information

Product details

Pharmacotherapeutic group

Therapeutic indication